HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A3016 Pozelimab (Anti-Complement C5) Pozelimab (Anti-Complement C5) is a fully human IgG4 monoclonal antibody targeting C5. It can be used for the research of complement-mediated diseases. MW :144.78 KD. Human IgG4SP
A2761 Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) is a fully human monoclonal immunoglobulin G2 antibody that targets the alpha4beta7 integrin and prevents interaction with MADCAM-1. It has the potential to be used in research on inflammatory bowel disease (IBD). MW: 143.8 kD. Human IgG2
A3017 Anti-PCLA Anti-PCLA is a fully human IgG4 monoclonal antibody targeting prostate cancer lipid-like antigen (PCLA) It can be used in treatment of prostate cancer. MW :145.52 KD. Human IgG1
A2762 Amlitelimab (Anti-TNFSF4 / OX40L / CD252) Amlitelimab (Anti-TNFSF4 / OX40L / CD252) is a nondepleting IgG4 human anti-OX40L monoclonal antibody with the potential to treat atopic dermatitis. MW: 145.94 kD. Human IgG4SP
A3018 Prolgolimab (Anti-PDCD1 / PD-1 / CD279) Prolgolimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG1 monoclonal antibody targeting PD-1. It can be used for the research of advanced melanoma. MW :145.14 KD. Human IgG1
A3019 Anti-MRC2 / CD280 Anti-MRC2 / CD280 is a monoclonal antibody targeting ENDO180. It can be used as therapeutic strategy of sarcoma subtypes, primary tumor and in metastatic disease. MW :142.92 KD. Human IgG1
A2764 Crenezumab (Anti-Amyloid Beta) Crenezumab (Anti-Amyloid Beta) is a fully humanized  immunoglobulin (Ig) G4 monoclonal antibody that targets amyloid beta (Abeta) with potential for use in Alzheimer's disease research. MW: 143.58 kD. Human IgG4SP
A3020 Quavonlimab (Anti-CTLA-4 / CD152) Quavonlimab (Anti-CTLA-4 / CD152) is a monoclonal antibody targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). It exhibits efficacy in first-line treatment of advanced non-small-cell lung cancer. MW :144.24 KD. Human IgG1
A2766 Gantenerumab (Anti-Amyloid Beta) Gantenerumab (Anti-Amyloid Beta) is a fully human IgG1 monoclonal antibody against beta-amyloid (Abeta40/42) used in the treatment of Alzheimer's disease. MW: 146.28 kD. Human IgG1
A3022 Ralpancizumab (Anti-PCSK9) Ralpancizumab (Anti-PCSK9) is a monoclonal antibody targeting selective proprotein convertase subtilisin kexin 9 (PCSK9). It has the potential in hemorrhagic stroke, hypercholesterolemic, dyslipidemia treatment. MW 145.28 KD. Human IgG2SA
A2767 GSK 933776 (Anti-Amyloid Beta) GSK 933776 (Anti-Amyloid Beta) is a humanized monoclonal antibody against beta-amyloid used in the treatment of Alzheimer's disease. MW: 145.34 kD. Human IgG1
A3023 Recaticimab (Anti-PCSK9) Recaticimab (Anti-PCSK9) is a humanized monoclonal antibody that targets PCSK9. It has potential application in hypercholesterolemia. MW :148.28 KD Human IgG1
A2768 Alomfilimab (Anti-ICOS / CD278) Alomfilimab (Anti-ICOS / CD278) is a human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. MW: 146.5 kD. Human IgG1
A3024 Anti-PCSK9 (RG7652) Anti-PCSK9 (RG7652) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). It exhibits potential efficacy in coronary heart disease (CHD). MW :144.84 KD. Human IgG1
A2770 Anti-ANGPT2 (MEDI3617) Anti-ANGPT2 (MEDI3617) is a human IgG1 kappa monoclonal antibody directed against the angiogenic cytokines angiopoietin-2 (Angpt2). MEDI3617 in combination with tremelimumab is used to treat advanced melanoma. MW: 145.82 kD. Human IgG2SA
A3026 Anti-ASIC1 Anti-ASIC1 is a mouse monoclonal antibody targeting acid-sensing ion channel-1 (ASIC1). It exhibits potential application in pain,neurodegenerative diseases, and psychiatric diseases. MW :144.04 KD. Human IgG1
A2771 Zansecimab (Anti-ANGPT2) Zansecimab (Anti-ANGPT2) is a humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2) with potential anti-angiogenic activity. MW: 145.74 kD. Human IgG4SP
A3027 Balstilimab (Anti-PDCD1 / PD-1 / CD279) Balstilimab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting the programmed cell death 1 (PD-1, PCD-1; PDCD1). It exhibits potential treatment of cervical cancer. MW :137.3 KD. Human IgG4SP
A2772 Anti-ANGPTL4 Anti-ANGPTL4 is a monoclonal antibody against Angiopoietin-like 4 (ANGPTL4) with potential anti-tumor and anti-angiogenic activity. MW: 146.12 KD. Human IgG1
A3028 Budigalimab (Anti-PDCD1 / PD-1 / CD279) Budigalimab (Anti-PDCD1 / PD-1 / CD279) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. It can be used in the treatment of advanced solid tumors. MW :145.84 KD. Human IgG1